
Ken Blount, PhD: Restoring the Gut Microbiota With RBX2660
RBX2660 was the first ever live microbiota therapeutic to gain approval from the FDA for rCDI.
In the latest iteration of data from the PUNCH-CD3 trial, investigators found a clonally-resolved metagenomic species (MSG)-based approach is the top choice for assessing engraftment among live biotherapeutic products bacterial populations.
In data presented during the
In the study, the investigators examined adult patients enrolled in the PUNCH CD3 trial with at least 1 recurrent
The patients in the RBX2660 group who achieved 8-week treatment success showed gut microbiota restoration to a composition and diversity similar to the healthy control group as soon as 1 week following treatment.
In addition, successful outcomes were significantly associated with greater levels of clonal engraftment from RBX2660 (P <0.001).
In an interview with HCPLive®, Blount described the importance of the trial and what are some of the opportunities to study RBX2660 further in the future.


























































